Auron Therapeutics

About Auron Therapeutics

Auron Therapeutics is a clinical-stage biotechnology company focused on targeting cell state plasticity to improve patient outcomes in oncology and inflammatory diseases. Their mission is to identify the root causes of diseases and deliver effective, durable therapies through AI-driven platforms and innovative drug development.

Products & Services

AURIGIN Platform:An AI-driven platform for identifying cell state-specific targets, disease models, and biomarkers to enhance drug discovery and development.

AUTX-703:A therapeutic program targeting advanced hematologic malignancies, currently in Phase 1 clinical trials, focusing on cancers with high mortality rates such as Acute Myeloid Leukemia (AML), Small-Cell Lung Cancer (SCLC), and Neuroendocrine Prostate Cancer (NEPC).

Specialties

Cell State Plasticity Oncology Inflammatory Disease AI/ML-Powered Drug Discovery Single Cell Genomic Data Analysis

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B T: - FT: Series B	A: 27000000 MR: - FA: $27 million FAN: 27000000	D: 2025-02-04 FD: 2025-02-04	9 investors

Series B Latest

2025-02-04

$27.0M

9 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

K

Katharine Yen

Founder & CEO

G

Glenn Goddard

Chief Financial Officer

D

David Millan

Chief Scientific Officer

T

Thomas Graeber

Chief Data Officer

L

Laura Antipov

Vice President, Portfolio Management

C

Caroline Almon

Vice President, Clinical Development

View 25 more team members with Pro

Unlock Full Team Directory

Recent News